antisense-oligonucleotide
(2)
AusperBio
AusperBio is a clinical-stage biopharmaceutical company operating in the United States and China that develops antisense oligonucleotide (ASO) therapies aimed at a functional cure for chronic hepatitis B. Built on its proprietary Med-Oligo ASO platform and targeted delivery technology, its lead candidate AHB-137 is an unconjugated ASO advancing into Phase III trials in China, with early data showing a 30% functional cure rate in a subset of patients. Founded in 2019 and headquartered in San Mateo, California, the company has raised over $200 million to date.
Trace Neuroscience
Trace Neuroscience is a South San Francisco biopharmaceutical company developing genomic medicines for neurodegenerative diseases, starting with ALS. Its lead program, TRCN-1023, is an antisense oligonucleotide designed to restore UNC13A protein function - a target genetically validated in roughly 97% of people living with ALS - by correcting the faulty RNA splicing caused by TDP-43 dysfunction. The company launched in November 2024 with a $101 million Series A led by Third Rock Ventures and entered the clinic in 2026.